ClinicalTrials.gg
CompletedNCT03635489Updated Oct 3, 2024Results posted

A Study of the Efficacy and Safety of Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

A Phase 3 interventional study of Paclitaxel and Bevacizumab in Ovarian Cancer, Fallopian Tube Cancer and Primary Peritoneal Cancer, sponsored by Hoffmann-La Roche. Completed at 16 sites in China. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-03.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 106 studies testing bevacizumab in Ovarian Neoplasms — 22 open to participants now, 32 under way, 9 of them phase 3. Bevacizumab · Ovarian Neoplasms.

Enrollment
34th of 106
100 · median 52
Started
2018
with 4 others
Phase 3
18 of 106
4 open now
Registered
66th of 106
by date
Lead sponsor
7 of 106
Hoffmann-La Roche

Among the 106 studies testing bevacizumab in Ovarian Neoplasms, this one is the 34th largest by enrollment, is one of 5 that started in 2018, is one of 18 in phase 3, and was the 66th registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 792 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

22 of the 106 studies testing bevacizumab in Ovarian Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

17 more — sign in →

By country, each count listing its studies:

All 22 open studies →

About bevacizumab

Bevacizumab: first FDA approval 2004 (AVASTIN), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 605 Ovarian Neoplasms studies recruiting now, 442 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 106 studies testing bevacizumab in Ovarian Neoplasms, or all of them as a file.
02

Study summary

This multicenter, double-blind, 2-arm, randomized study will evaluate the efficacy and safety of bevacizumab plus paclitaxel and caboplatin compared with placebo plus paclitaxel and caboplatin in Chinese participants with newly diagnosed, previously untreated Stage III or Stage IV epithelial ovarian, fallopian tube, or primary peritoneal cancer. Participants whose disease has not progressed after six cycles of paclitaxel and carboplatin with either bevacizumab or placebo will continue treatment with either bevacizumab or placebo until disease progression, unacceptable toxicity, or a maximum of 22 cycles, whichever occurs first.

03

Conditions studied

  • Ovarian Cancer
  • Fallopian Tube Cancer
  • Primary Peritoneal Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants receiving a histologic diagnosis of epithelial ovarian cancer (EOC), peritoneal primary carcinoma, or fallopian tube cancer.
  • (ECOG) performance status of 0, 1, or 2.
  • of at least 12 weeks.
  • Adequate hematological, liver, renal and neurologic functions.
  • For participants who receive therapeutic anticoagulation: stable anticoagulant regimen.
  • Enrollment between 1 and 12 weeks after initial surgery is performed for the combined purpose of diagnosis, staging, and cytoreduction

Exclusion criteria

Exclusion Criteria:

  • Current diagnosis of borderline epithelial ovarian tumor or recurrent invasive epithelial ovarian, primary peritoneal, or fallopian tube cancer treated with surgery only.
  • Prior radiotherapy to any portion of the abdominal cavity or pelvis.
  • Prior chemotherapy for any abdominal or pelvic tumor, including chemotherapy for ovarian, primary peritoneal, or fallopian tube cancer.
  • Any prior targeted therapy (including, but not limited to, vaccines, antibodies, or tyrosine kinase inhibitors) or hormonal therapy for management of their epithelial ovarian or peritoneal primary cancer.
  • Synchronous primary endometrial cancer.
  • Have a prior history of primary endometrial cancer, except: Stage not greater than Stage IB; no more than superficial myometrial invasion, without vascular or lymphatic invasion; no poorly differentiated subtypes, including papillary serous, clear cell, or other International Federation of Gynecological Oncologists (FIGO) Grade 3 lesions.
  • Cancer present within the last 5 years with the exception of non-melanoma-related skin cancers and other specific or whose previous cancer treatment contraindicates study treatment.
  • Active virus (HBV) infection (chronic or acute) or active virus (HCV) infection.
  • Serious non-healing wounds, ulcers, or bone fractures.
  • Patients with cardiovascular disease.
  • Have known to Chinese hamster ovary cell products or other recombinant human or humanized antibodies.
  • Have known sensitivity to any component of paclitaxel.
  • Undergo major surgical procedure within 28 days prior to randomization or anticipated during the course of the study.
  • Have core or other minor surgical procedures within 7 days prior to the first dose of bevacizumab/placebo.
  • History or evidence of thrombotic disorders within the last 6 months prior to enrollment.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    Bevacizumab + Paclitaxel + Carboplatin

    Participants will receive paclitaxel, carboplatin intravenous (IV) infusion on Day 1 of each 21-day cycle for a total of 6 cycles. Bevacizumab IV infusion will start at Cycle 2 for 5 cycles, followed by maintenance therapy up to a maximum of 22 cycles or until disease progression, unacceptable toxicity, or withdrawal, whichever occurs first.

    Drug: Paclitaxel · Drug: Bevacizumab · Drug: Carboplatin

  • Placebo comparator
    Placebo + Paclitaxel + Carboplatin

    Participants will receive paclitaxel, carboplatin IV infusion on Day 1 of each 21-day cycle for a total of 6 cycles. Placebo IV infusion will start at Cycle 2 for 5 cycles, followed by maintenance therapy up to a maximum of 22 cycles or until disease progression, unacceptable toxicity, or withdrawal, whichever occurs first.

    Drug: Paclitaxel · Drug: Carboplatin · Drug: Placebo

Interventions

  • 175 mg/m\^2 IV infusion on Day 1 of each 21-day cycle.

  • 15 mg/kg IV infusion on Day 1 of each 21-day cycle.

    Also known as: Avastin

  • Area Under the Curve (AUC) of 6 mg/ml/min on Day 1 of each 21-day cycle.

  • DrugPlacebo

    Placebo matched to bevacizumab IV infusion on Day 1 of each 21-day cycle.

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS)

    PFS was defined as time from randomization to the first occurrence of disease progression, as assessed by the Investigator using RECIST v1.1, or death from any cause, whichever occurs first.

    Time frame: Randomization up to disease progression or death from any cause, whichever occurs first (up to approximately 24 months)

Secondary outcomes

  1. Overall Survival (OS)

    OS was defined as the time from the date of randomization to the date of death from any cause.

    Time frame: Randomization up to to death from any cause (up to approximately 54.1 months)

  2. Objective Response Rate (ORR)

    ORR was defined as the proportion of participants with complete response (CR) or partial response (PR) as assessed by investigator according to RECIST v.1.1.

    Time frame: Randomization up to disease progression or death from any cause, whichever occurs first (up to approximately 24 months)

  3. Duration of Response (DOR)

    DOR was defined as the time from when response (CR or PR) was first documented to first documented disease progression,as assessed by the Investigator using RECIST v1.1, or death from any cause, whichever occurred first. DOR was evaluated for participants who had a objective response of CR or PR.

    Time frame: From the date of first occurrence of a complete or partial response until disease progression or death from any cause (up to approximately 24 months)

  4. Percentage of Participants Who Report a Clinically Meaningful Improvement in Patient-Reported Abdominal Pain

    A clinically meaningful improvement in patient-reported abdominal pain or bloating was defined as a ≥10-point decrease from the linearly transformed 0-100 point baseline symptom scale score on each of two items from the Abdominal/Gastrointestinal Symptom Scale of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire - Ovarian Cancer Module (QLQ-OV28).

    Time frame: From randomization to the end of treatment/discontinuation (up to approximately 70 weeks), and during follow-up period (up to approximately 24 months)

  5. Percentage of Participants Who Report a Clinically Meaningful Improvement in Patient-Reported Bloating

    A clinically meaningful improvement in patient-reported abdominal pain or bloating was defined as a ≥10-point decrease from the linearly transformed 0-100 point baseline symptom scale score on each of two items from the Abdominal/Gastrointestinal Symptom Scale of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire - Ovarian Cancer Module (QLQ-OV28).

    Time frame: From randomization to the end of treatment/discontinuation (up to approximately 70 weeks), and during follow-up period (up to approximately 24 months)

  6. Percentage of Participants Who Report a Clinically Meaningful Improvement in Patient-Reported Function (Physical)

    A clinically meaningful improvement in patient-reported function and HRQoL was defined as a \>10-point increase from the linearly transformed 0-100 point baseline scale score on each of the four functional (physical, role, emotional, social) scales and global health status/HRQoL scale of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire - Core 30 (QLQ-C30).

    Time frame: From randomization to the end of treatment/discontinuation (up to approximately 70 weeks), and during follow-up period (up to approximately 24 months)

  7. Percentage of Participants Who Report a Clinically Meaningful Improvement in Patient-Reported Function (Role)

    A clinically meaningful improvement in patient-reported function and HRQoL was defined as a \>10-point increase from the linearly transformed 0-100 point baseline scale score on each of the four functional (physical, role, emotional, social) scales and global health status/HRQoL scale of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire - Core 30 (QLQ-C30).

    Time frame: From randomization to the end of treatment/discontinuation (up to approximately 70 weeks), and during follow-up period (up to approximately 24 months)

  8. Percentage of Participants Who Report a Clinically Meaningful Improvement in Patient-Reported Function (Social)

    A clinically meaningful improvement in patient-reported function and HRQoL was defined as a \>10-point increase from the linearly transformed 0-100 point baseline scale score on each of the four functional (physical, role, emotional, social) scales and global health status/HRQoL scale of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire - Core 30 (QLQ-C30).

    Time frame: From randomization to the end of treatment/discontinuation (up to approximately 70 weeks), and during follow-up period (up to approximately 24 months)

  9. Percentage of Participants Who Report a Clinically Meaningful Improvement in Patient-Reported Function (Emotional)

    A clinically meaningful improvement in patient-reported function and HRQoL was defined as a \>10-point increase from the linearly transformed 0-100 point baseline scale score on each of the four functional (physical, role, emotional, social) scales and global health status/HRQoL scale of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire - Core 30 (QLQ-C30).

    Time frame: From randomization to the end of treatment/discontinuation (up to approximately 70 weeks), and during follow-up period (up to approximately 24 months)

  10. Pecentage of Participants Who Report a Clinically Meaningful Improvement in Patient-Reported Health Related Quality of Life (HRQoL)

    A clinically meaningful improvement in patient-reported function and HRQoL was defined as a \>10-point increase from the linearly transformed 0-100 point baseline scale score on each of the four functional (physical, role, emotional, social) scales and global health status/HRQoL scale of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire - Core 30 (QLQ-C30).

    Time frame: From randomization to the end of treatment/discontinuation (up to approximately 70 weeks), and during follow-up period (up to approximately 24 months)

  11. Percentage of Participants With Adverse Events (AEs)

    Time frame: From randomization up to 90 days after last dose of study treatment or until initiation of new anti-cancer therapy (up to approximately 76 weeks)

07

Results

Posted Mar 17, 2023

Participant flow

This study was conducted at 16 centers in mainland China.

Participant flow — Overall Study
MilestonePlacebo + Paclitaxel + CarboplatinBevacizumab + Paclitaxel + Carboplatin
Started4951
Completed00
Not completed4951
Withdrew: Death1913
Withdrew: Lost to follow-up12
Withdrew: Withdrawal by subject12
Withdrew: Study ended by sponsor2834

Outcome measures

PrimaryProgression-Free Survival (PFS)

PFS was defined as time from randomization to the first occurrence of disease progression, as assessed by the Investigator using RECIST v1.1, or death from any cause, whichever occurs first.

Time frame:
Randomization up to disease progression or death from any cause, whichever occurs first (up to approximately 24 months)
Reported as:
Median · months
Progression-Free Survival (PFS)
monthsPlacebo + Paclitaxel + CarboplatinBevacizumab + Paclitaxel + Carboplatin
Progression-Free Survival (PFS)12.32 (9.53 to 15.05)22.57 (18.60 to NA)
Statistical analysis
  • Placebo + Paclitaxel + Carboplatin vs Bevacizumab + Paclitaxel + Carboplatin · Regression, Cox · p = <.0001 · Hazard ratio (hr): 0.30 · 95% CI 0.17 to 0.53
  • Placebo + Paclitaxel + Carboplatin vs Bevacizumab + Paclitaxel + Carboplatin · Regression, Cox · p = <.0001 · Hazard ratio (hr): 0.34 · 95% CI 0.20 to 0.58
SecondaryOverall Survival (OS)

OS was defined as the time from the date of randomization to the date of death from any cause.

Time frame:
Randomization up to to death from any cause (up to approximately 54.1 months)
Reported as:
Median · months
Overall Survival (OS)
monthsPlacebo + Paclitaxel + CarboplatinBevacizumab + Paclitaxel + Carboplatin
Overall Survival (OS)48.89 (40.31 to NA)NA (NA to NA)
Statistical analysis
  • Placebo + Paclitaxel + Carboplatin vs Bevacizumab + Paclitaxel + Carboplatin · Hazard ratio (hr): 0.60 · 95% CI 0.30 to 1.21
SecondaryObjective Response Rate (ORR)

ORR was defined as the proportion of participants with complete response (CR) or partial response (PR) as assessed by investigator according to RECIST v.1.1.

Time frame:
Randomization up to disease progression or death from any cause, whichever occurs first (up to approximately 24 months)
Reported as:
Number · percentage of participants
Objective Response Rate (ORR)
percentage of participantsPlacebo + Paclitaxel + CarboplatinBevacizumab + Paclitaxel + Carboplatin
Objective Response Rate (ORR)92.9 (76.50 to 99.12)95.8 (78.88 to 99.89)
SecondaryDuration of Response (DOR)

DOR was defined as the time from when response (CR or PR) was first documented to first documented disease progression,as assessed by the Investigator using RECIST v1.1, or death from any cause, whichever occurred first. DOR was evaluated for participants who had a objective response of CR or PR.

Time frame:
From the date of first occurrence of a complete or partial response until disease progression or death from any cause (up to approximately 24 months)
Reported as:
Median · months
Duration of Response (DOR)
monthsPlacebo + Paclitaxel + CarboplatinBevacizumab + Paclitaxel + Carboplatin
Duration of Response (DOR)8.87 (7.56 to 13.14)16.10 (10.81 to NA)
SecondaryPercentage of Participants Who Report a Clinically Meaningful Improvement in Patient-Reported Abdominal Pain

A clinically meaningful improvement in patient-reported abdominal pain or bloating was defined as a ≥10-point decrease from the linearly transformed 0-100 point baseline symptom scale score on each of two items from the Abdominal/Gastrointestinal Symptom Scale of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire - Ovarian Cancer Module (QLQ-OV28).

Time frame:
From randomization to the end of treatment/discontinuation (up to approximately 70 weeks), and during follow-up period (up to approximately 24 months)
Reported as:
Number · percentage of participants
Percentage of Participants Who Report a Clinically Meaningful Improvement in Patient-Reported Abdominal Pain
percentage of participantsPlacebo + Paclitaxel + CarboplatinBevacizumab + Paclitaxel + Carboplatin
Cycle 4 Day 137.0 (23.21 to 52.45)31.3 (18.66 to 46.25)
Cycle 7 Day 140.9 (26.34 to 56.75)42.1 (26.31 to 58.18)
Cycle 13 Day 148.4 (30.15 to 66.94)40.0 (23.87 to 57.89)
Cycle 22 Day 137.5 (15.20 to 64.57)48.0 (27.80 to 68.69)
Treatment Completion / Early Termination Visit37.8 (23.77 to 53.46)45.2 (29.85 to 61.33)
Survival Follow Up 3 Months37.0 (19.40 to 57.63)33.3 (18.56 to 50.97)
Survival Follow Up 6 Months33.3 (11.82 to 61.62)38.1 (18.11 to 61.56)
Survival Follow Up 9 Months50.0 (15.70 to 84.30)46.2 (19.22 to 74.87)
Survival Follow Up 12 Months14.3 (0.36 to 57.87)42.9 (9.90 to 81.59)
Survival Follow Up 18 Months—66.7 (9.43 to 99.16)
Survival Follow Up 24 Months—0 (0 to 97.50)
SecondaryPercentage of Participants Who Report a Clinically Meaningful Improvement in Patient-Reported Bloating

A clinically meaningful improvement in patient-reported abdominal pain or bloating was defined as a ≥10-point decrease from the linearly transformed 0-100 point baseline symptom scale score on each of two items from the Abdominal/Gastrointestinal Symptom Scale of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire - Ovarian Cancer Module (QLQ-OV28).

Time frame:
From randomization to the end of treatment/discontinuation (up to approximately 70 weeks), and during follow-up period (up to approximately 24 months)
Reported as:
Number · percentage of participants
Percentage of Participants Who Report a Clinically Meaningful Improvement in Patient-Reported Bloating
percentage of participantsPlacebo + Paclitaxel + CarboplatinBevacizumab + Paclitaxel + Carboplatin
Cycle 4 Day 126.1 (14.27 to 41.13)33.3 (20.40 to 48.41)
Cycle 7 Day 136.4 (22.41 to 52.23)47.4 (30.98 to 64.18)
Cycle 13 Day 129.0 (14.22 to 48.04)31.4 (16.85 to 49.29)
Cycle 22 Day 125.0 (7.27 to 52.38)40.0 (21.13 to 61.33)
Treatment Completion / Early Termination Visit33.3 (20.00 to 48.95)33.3 (19.57 to 49.55)
Survival Follow Up 3 Months25.9 (11.11 to 46.28)33.3 (18.56 to 50.97)
Survival Follow Up 6 Months46.7 (21.27 to 73.41)19.0 (5.45 to 41.91)
Survival Follow Up 9 Months25.0 (3.19 to 65.09)23.1 (5.04 to 53.81)
Survival Follow Up 12 Months28.6 (3.67 to 70.96)28.6 (3.67 to 70.96)
Survival Follow Up 18 Months—66.7 (9.43 to 99.16)
Survival Follow Up 24 Months—0 (0 to 97.50)
SecondaryPercentage of Participants Who Report a Clinically Meaningful Improvement in Patient-Reported Function (Physical)

A clinically meaningful improvement in patient-reported function and HRQoL was defined as a \>10-point increase from the linearly transformed 0-100 point baseline scale score on each of the four functional (physical, role, emotional, social) scales and global health status/HRQoL scale of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire - Core 30 (QLQ-C30).

Time frame:
From randomization to the end of treatment/discontinuation (up to approximately 70 weeks), and during follow-up period (up to approximately 24 months)
Reported as:
Number · percentage of participants
Percentage of Participants Who Report a Clinically Meaningful Improvement in Patient-Reported Function (Physical)
percentage of participantsPlacebo + Paclitaxel + CarboplatinBevacizumab + Paclitaxel + Carboplatin
Cycle 4 Day 117.4 (7.82 to 31.42)16.7 (7.48 to 30.22)
Cycle 7 Day 118.2 (8.19 to 32.71)18.4 (7.74 to 34.33)
Cycle 13 Day 145.2 (27.32 to 63.97)34.3 (19.13 to 52.21)
Cycle 22 Day 143.8 (19.75 to 70.12)36.0 (17.97 to 57.48)
Treatment Completion / Early Termination Visit31.1 (18.17 to 46.65)31.0 (17.62 to 47.09)
Survival Follow Up 3 Months44.4 (25.48 to 64.67)27.8 (14.20 to 45.19)
Survival Follow Up 6 Months13.3 (1.66 to 40.46)23.8 (8.22 to 47.17)
Survival Follow Up 9 Months12.5 (0.32 to 52.65)23.1 (5.04 to 53.81)
Survival Follow Up 12 Months14.3 (0.36 to 57.87)28.6 (3.67 to 70.96)
Survival Follow Up 18 Months—0 (0 to 70.76)
Survival Follow Up 24 Months—0 (0 to 97.50)
SecondaryPercentage of Participants Who Report a Clinically Meaningful Improvement in Patient-Reported Function (Role)

A clinically meaningful improvement in patient-reported function and HRQoL was defined as a \>10-point increase from the linearly transformed 0-100 point baseline scale score on each of the four functional (physical, role, emotional, social) scales and global health status/HRQoL scale of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire - Core 30 (QLQ-C30).

Time frame:
From randomization to the end of treatment/discontinuation (up to approximately 70 weeks), and during follow-up period (up to approximately 24 months)
Reported as:
Number · percentage of participants
Percentage of Participants Who Report a Clinically Meaningful Improvement in Patient-Reported Function (Role)
percentage of participantsPlacebo + Paclitaxel + CarboplatinBevacizumab + Paclitaxel + Carboplatin
Cycle 4 Day 134.8 (21.35 to 50.25)31.3 (18.66 to 46.25)
Cycle 7 Day 125.0 (13.19 to 40.34)36.8 (21.81 to 54.01)
Cycle 13 Day 145.2 (27.32 to 63.97)48.6 (31.38 to 66.01)
Cycle 22 Day 150.0 (24.65 to 75.35)40.0 (21.13 to 61.33)
Treatment Completion / Early Termination Visit40.0 (25.70 to 55.67)42.9 (27.72 to 59.04)
Survival Follow Up 3 Months48.1 (28.67 to 68.05)33.3 (18.56 to 50.97)
Survival Follow Up 6 Months40.0 (16.34 to 67.71)42.9 (21.82 to 65.98)
Survival Follow Up 9 Months37.5 (8.52 to 75.51)30.8 (9.09 to 61.43)
Survival Follow Up 12 Months42.9 (9.90 to 81.59)57.1 (18.41 to 90.10)
Survival Follow Up 18 Months—33.3 (0.84 to 90.57)
Survival Follow Up 24 Months—0 (0 to 97.50)
SecondaryPercentage of Participants Who Report a Clinically Meaningful Improvement in Patient-Reported Function (Social)

A clinically meaningful improvement in patient-reported function and HRQoL was defined as a \>10-point increase from the linearly transformed 0-100 point baseline scale score on each of the four functional (physical, role, emotional, social) scales and global health status/HRQoL scale of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire - Core 30 (QLQ-C30).

Time frame:
From randomization to the end of treatment/discontinuation (up to approximately 70 weeks), and during follow-up period (up to approximately 24 months)
Reported as:
Number · percentage of participants
Percentage of Participants Who Report a Clinically Meaningful Improvement in Patient-Reported Function (Social)
percentage of participantsPlacebo + Paclitaxel + CarboplatinBevacizumab + Paclitaxel + Carboplatin
Cycle 4 Day 128.3 (15.99 to 43.46)29.2 (16.95 to 44.06)
Cycle 7 Day 127.3 (14.96 to 42.79)28.9 (15.42 to 45.90)
Cycle 13 Day 138.7 (21.85 to 57.81)28.6 (14.64 to 46.30)
Cycle 22 Day 143.8 (19.75 to 70.12)36.0 (17.97 to 57.48)
Treatment Completion / Early Termination Visit28.9 (16.37 to 44.31)33.3 (19.57 to 49.55)
Survival Follow Up 3 Months33.3 (16.52 to 53.96)47.2 (30.41 to 64.51)
Survival Follow Up 6 Months26.7 (7.79 to 55.10)28.6 (11.28 to 52.18)
Survival Follow Up 9 Months37.5 (8.52 to 75.51)7.7 (0.19 to 36.03)
Survival Follow Up 12 Months28.6 (3.67 to 70.96)28.6 (3.67 to 70.96)
Survival Follow Up 18 Months—66.7 (9.43 to 99.16)
Survival Follow Up 24 Months—100 (2.50 to 100)
SecondaryPercentage of Participants Who Report a Clinically Meaningful Improvement in Patient-Reported Function (Emotional)

A clinically meaningful improvement in patient-reported function and HRQoL was defined as a \>10-point increase from the linearly transformed 0-100 point baseline scale score on each of the four functional (physical, role, emotional, social) scales and global health status/HRQoL scale of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire - Core 30 (QLQ-C30).

Time frame:
From randomization to the end of treatment/discontinuation (up to approximately 70 weeks), and during follow-up period (up to approximately 24 months)
Reported as:
Number · percentage of participants
Percentage of Participants Who Report a Clinically Meaningful Improvement in Patient-Reported Function (Emotional)
percentage of participantsPlacebo + Paclitaxel + CarboplatinBevacizumab + Paclitaxel + Carboplatin
Cycle 4 Day 18.7 (2.42 to 20.79)22.9 (12.03 to 37.31)
Cycle 7 Day 113.6 (5.17 to 27.35)21.1 (9.55 to 37.32)
Cycle 13 Day 19.7 (2.04 to 25.75)25.7 (12.49 to 43.26)
Cycle 22 Day 118.8 (4.05 to 45.65)28.0 (12.07 to 49.39)
Treatment Completion / Early Termination Visit11.1 (3.71 to 24.05)21.4 (10.30 to 36.81)
Survival Follow Up 3 Months22.2 (8.62 to 42.26)27.8 (14.20 to 45.19)
Survival Follow Up 6 Months6.7 (0.17 to 31.95)38.1 (18.11 to 61.56)
Survival Follow Up 9 Months12.5 (0.32 to 57.87)38.5 (13.86 to 68.42)
Survival Follow Up 12 Months14.3 (0.36 to 57.87)28.6 (3.67 to 70.96)
Survival Follow Up 18 Months—0 (0 to 70.76)
Survival Follow Up 24 Months—0 (0 to 97.50)
SecondaryPecentage of Participants Who Report a Clinically Meaningful Improvement in Patient-Reported Health Related Quality of Life (HRQoL)

A clinically meaningful improvement in patient-reported function and HRQoL was defined as a \>10-point increase from the linearly transformed 0-100 point baseline scale score on each of the four functional (physical, role, emotional, social) scales and global health status/HRQoL scale of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire - Core 30 (QLQ-C30).

Time frame:
From randomization to the end of treatment/discontinuation (up to approximately 70 weeks), and during follow-up period (up to approximately 24 months)
Reported as:
Number · percentage of participants
Pecentage of Participants Who Report a Clinically Meaningful Improvement in Patient-Reported Health Related Quality of Life (HRQoL)
percentage of participantsPlacebo + Paclitaxel + CarboplatinBevacizumab + Paclitaxel + Carboplatin
Cycle 4 Day 119.6 (9.36 to 33.91)33.3 (20.40 to 48.41)
Cycle 7 Day 134.1 (20.49 to 49.92)34.2 (19.63 to 51.35)
Cycle 13 Day 138.7 (21.85 to 57.81)34.3 (19.13 to 52.21)
Cycle 22 Day 143.8 (19.75 to 70.12)44.0 (24.40 to 65.07)
Treatment Completion / Early Termination Visit31.1 (18.17 to 46.65)40.5 (25.63 to 56.72)
Survival Follow Up 3 Months29.6 (13.75 to 50.18)38.9 (23.14 to 56.54)
Survival Follow Up 6 Months33.3 (11.82 to 61.62)28.6 (11.28 to 52.18)
Survival Follow Up 9 Months12.5 (0.32 to 52.65)23.1 (5.04 to 53.81)
Survival Follow Up 12 Months14.3 (0.36 to 57.87)42.9 (9.90 to 81.59)
Survival Follow Up 18 Months—33.3 (0.84 to 90.57)
Survival Follow Up 24 Months—0 (0 to 97.50)
SecondaryPercentage of Participants With Adverse Events (AEs)
Time frame:
From randomization up to 90 days after last dose of study treatment or until initiation of new anti-cancer therapy (up to approximately 76 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With Adverse Events (AEs)
percentage of participantsPlacebo + Paclitaxel + CarboplatinBevacizumab + Paclitaxel + Carboplatin
Percentage of Participants With Adverse Events (AEs)100100

Adverse events

Collected over All-cause mortality: From randomization up to end of follow up (54.1 months) AEs and SAEs: From randomization up to 90 days after last dose of study treatment or until initiation of new anti-cancer therapy (up to approximately 76 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo + Paclitaxel + Carboplatin19/50 (38%)16/50 (32%)49/50 (98%)
Bevacizumab + Paclitaxel + Carboplatin13/49 (26.5%)17/49 (34.7%)49/49 (100%)
Most frequent serious events
Showing 10 of 26
Most frequent serious events
EventPlacebo + Paclitaxel + CarboplatinBevacizumab + Paclitaxel + Carboplatin
MyelosuppressionBlood and lymphatic system disorders5/504/49
Platelet count decreasedInvestigations5/503/49
AnaemiaBlood and lymphatic system disorders3/500/49
Neutrophil count decreasedInvestigations3/500/49
IleusGastrointestinal disorders1/502/49
Intestinal obstructionGastrointestinal disorders2/502/49
GranulocytopeniaBlood and lymphatic system disorders0/501/49
Mechanical ileusGastrointestinal disorders0/501/49
NauseaGastrointestinal disorders0/501/49
Pancreatitis acuteGastrointestinal disorders0/501/49
Most frequent other events
Showing 10 of 79
Most frequent other events
EventPlacebo + Paclitaxel + CarboplatinBevacizumab + Paclitaxel + Carboplatin
AlopeciaSkin and subcutaneous tissue disorders41/5043/49
Neutrophil count decreasedInvestigations32/5039/49
AnaemiaBlood and lymphatic system disorders35/5038/49
White blood cell count decreasedInvestigations29/5038/49
Platelet count decreasedInvestigations26/5029/49
NauseaGastrointestinal disorders25/5020/49
ProteinuriaRenal and urinary disorders3/5022/49
VomitingGastrointestinal disorders21/5013/49
Alanine aminotransferase increasedInvestigations19/5017/49
HypertensionVascular disorders9/5018/49

Baseline characteristics

Age, Continuous
Age, Continuous(years)Placebo + Paclitaxel + CarboplatinBevacizumab + Paclitaxel + CarboplatinTotal
Mean53.1 ± 8.454.1 ± 8.253.6 ± 8.3
Sex: Female, Male
Sex: Female, Male(Participants)Placebo + Paclitaxel + CarboplatinBevacizumab + Paclitaxel + CarboplatinTotal
Female4951100
Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo + Paclitaxel + CarboplatinBevacizumab + Paclitaxel + CarboplatinTotal
Hispanic or Latino000
Not Hispanic or Latino4951100
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo + Paclitaxel + CarboplatinBevacizumab + Paclitaxel + CarboplatinTotal
American Indian or Alaska Native000
Asian4951100
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
08

Study locations

16 sites
  • Beijing Obstetrics and Gynecology Hospital, Capital Medical University
    Beijing City, 100006, China
  • the First Hospital of Jilin University
    Changchun, 130021, China
  • Jilin Cancer Hospital
    Changchun, 132013, China
  • Xiangya Hospital Central South University
    Changsha City, 410008, China
  • West China Second University Hospital
    Chengdu City, 610066, China
  • Fujian Cancer Hospital
    Fuzhou, 350014, China
  • Sun Yet-sen University Cancer Center
    Guangzhou City, 510663, China
  • Zhejiang Cancer Hospital; Zhejiang Cancer Hospital cancer department
    Hangzhou City, 310022, China
  • Harbin Medical University Cancer Hospital
    Harbin, 150081, China
  • Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School
    Nanjing City, 210008, China
  • Guangxi Cancer Hospital of Guangxi Medical University
    Nanning City, 530021, China
  • Nantong Tumor Hospital
    Nantong City, 226361, China
  • Fudan University Shanghai Cancer Center
    Shanghai City, 200120, China
  • Tianjin Medical University General Hospital
    Tianjin, 300052, China
  • First Affiliated Hospital of Medical College of Xi'an Jiaotong University
    Xi'an, 710061, China
  • Henan Cancer Hospital
    Zhengzhou, 450008, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2018 to primary completion in May 2021, 33 months.

Results were first posted in Mar 2023, 1 year 9 months after primary completion.

Of 73 industry-sponsored phase 3 interventional studies under Ovarian Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 72. This study's 33 months is below that.

Counting every sponsor, half of 125 studies reached it within 59 months; a quarter within 37 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2018
First posted
Aug 17, 2018
StartActual
Aug 15, 2018
Primary completionActual
May 26, 2021
CompletionActual
May 11, 2023
Results first posted
Mar 17, 2023
Last update
Oct 3, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 3, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03635489
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Aug 17, 2018
Start date
Aug 15, 2018
Primary completion
May 26, 2021
Completion
May 11, 2023
Results posted
Mar 17, 2023
Last update
Oct 3, 2024

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bevacizumab

Start the discussion